Table 2 Health utilities regression

From: SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer

Variable

Coef.

S.E.

N-observations

16,091

 

N-patients

1757

 

Health states (ref: disease free)

  

 On treatment

−0.0394***

0.00408

 Recurrence

−0.0578***

0.0139

Arm: 6 months

−0.0154*

0.00730

Characteristics

  

 CAPOX

0.00402

0.00783

 High risk

−0.00911

0.00724

 Male

0.0159*

0.00733

 Age

0.00162***

0.000429

 Ethnic (ref: White/Caucasian)

  

  African/Caribbean

−0.0810*

0.0385

  South Asian

−0.145**

0.0536

  Chinese

−0.0447

0.0772

  Other

0.0178

0.0217

Constant

0.866***

0.00944

  1. Standard errors (S.E.) clustered at the patient level
  2. P-values: *P < 0.05, **P < 0.01, ***P < 0.001
  3. N-observations refer to the number of EQ-5D questionnaires reported in total by the N-patients included in the estimation
  4. The constant in the model refers to a 65-year-old female patient, in disease-free health state in the 3 months arm, receiving FOLFOX treatment, with low risk stage III and White/Caucasian ethnicity
Back to article page